Table 3 Results of the cost-per-response analysis after 6 and 12 months
Outcome | Parameter | Month | Overall | Secukinumab | TNFi |
|---|---|---|---|---|---|
DAS28 (good/moderate) | Number of evaluated patients (N) | 6 | 307 | 128 | 159 |
12 | 296 | 125 | 148 | ||
Cost-per-patient (€) | 6 | €9571 | €9298 | €9420 | |
12 | €14,879 | €14,155 | €14,668 | ||
Response rate (%) | 6 | 71.7% | 73.4% | 71.7% | |
12 | 67.9% | 69.6% | 70.3% | ||
Cost-per-responder ratio (€) | 6 | €13,356 | €12,661 | €13,138 | |
12 | €21,912 | €20,337 | €20,874 | ||
ACR20 | Number of evaluated patients (N) | 6 | 194 | 75 | 105 |
12 | 189 | 74 | 100 | ||
Cost-per-patient (€) | 6 | €9804 | €9658 | €9377 | |
12 | €14,877 | €14,674 | €14,188 | ||
Response rate (%) | 6 | 41.2% | 45.3% | 39.0% | |
12 | 34.9% | 35.1% | 36.0% | ||
Cost-per-responder ratio (€) | 6 | €23,775 | €21,305 | €24,016 | |
12 | €42,604 | €41,765 | €39,412 | ||
ACR50 | Number of evaluated patients (N) | 6 | 194 | 75 | 105 |
12 | 191 | 75 | 101 | ||
Cost-per-patient (€) | 6 | €9804 | €9658 | €9378 | |
12 | €14,832 | €14,612 | €14,158 | ||
Response rate (%) | 6 | 29.4% | 33.3% | 26.7% | |
12 | 26.7% | 29.3% | 25.7% | ||
Cost-per-responder ratio (€) | 6 | €33,368 | €28,975 | €35,166 | |
12 | €55,548 | €49,815 | €54,997 |